Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039194 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01039194 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 18 participants.
The verdict
NCT01039194, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.
Interventions
- DRUG BMS-708163
- DRUG galantamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039194
The ClinicalTrials.gov registry entry for NCT01039194 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-708163 is the first listed.
NCT01039194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01039194 about?
NCT01039194 is a clinical study titled "Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)". The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.
What is the current status of trial NCT01039194?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01039194?
The interventions under investigation include: BMS-708163 (DRUG), galantamine (DRUG).
Who is sponsoring clinical trial NCT01039194?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.